Chloroquine/hydroxychloroquine warning from the FDA
US FDA
The FDA is warning the public that chloroquine and hydroxychloroquine should not be taken for COVID-19 outside a hospital or clinical trial setting, as the drugs confer potentially life-threatening cardiac risks. A Nature Medicine study published on Friday found that a cohort of 84 COVID-19 patients given the combination of hydroxychloroquine plus azithromycin had their average QTc interval increase from 435 ms at baseline to a maximal average value of 463 ms. Roughly 11% had a QTC interval above 500 ms, “a known marker of high risk of malignant arrhythmia and sudden cardiac death.”
Chloroquine/hydroxychloroquine warning from the FDA